Posted by Michael Wonder on 03 Nov 2020
Provention Bio completes rolling submission of the biologics license application for teplizumab for the delay or prevention of clinical type 1 diabetes in at risk individuals
2 November 2020 - Submission of chemistry, manufacturing and controls and administrative information modules represent completion of the Company's submission for teplizumab.
Provention Bio today announced the completion of the rolling submission of a biologics license application to the U.S. FDA for teplizumab for the delay or prevention of clinical type one diabetes in at risk individuals with the submission of the chemistry, manufacturing and controls and administrative information modules.
